On May 1, 2024, TG Therapeutics will host a conference call discussing Q1 2024 financials and providing a yearly outlook, with BRIUMVI® MS approval mentioned.
TG Therapeutics, a commercial-stage biopharma firm focused on B-cell diseases, will host a conference call on May 1, 2024, at 8:30 AM ET, discussing first quarter 2024 financial results and providing a business outlook for the year. The call will be accessible via 1-877-407-8029 (U.S.) or 1-201-689-8029 (international), with an audio recording available for 30 days. TG Therapeutics received FDA approval for BRIUMVI® to treat relapsing forms of multiple sclerosis.
April 30, 2024
3 Articles